

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 through 6 canceled.

7. (Currently Amended) A method of ~~directing the navigation of physiological tracking tubular structures that express Robo-4 receptor away from a target cell mass~~ preventing guided navigation of endothelial tubes during angiogenesis to a target cell mass, wherein said endothelial tubes express a Robo-4 receptor, the method comprising expressing a ligand of said Robo-4 receptor in said target cell mass and allowing binding between the ligand and said Robo-4 receptor activating said Robo-4 receptor, wherein activating said Robo-4 receptor inhibits the guided navigation of the endothelial tubes toward the target cell mass.

8. (Currently Amended) The method of claim 7, wherein the ligand comprises a Slit ligand activating said Robo-4 receptor comprises providing a ligand capable of activating said Robo-4 receptor and exposing said endothelial tubes to the ligand, wherein said exposure of said endothelial tubes to said ligand inhibits the guided navigation of the endothelial tubes toward the target cell mass.

9. (Currently Amended) The method of claim 8, wherein said physiological

~~tracking tubular structures comprise endothelial tubes~~ providing a ligand capable of activating said Robo-4 receptor comprises providing a Slit ligand.

Claims 10 through 18 canceled.

19. (Currently Amended) A method of preventing angiogenesis in endothelium tissue expressing Robo-4 receptor, the method comprising, activating said Robo-4 receptor, wherein activating said Robo-4 receptor inhibits migration of endothelial cells.

20. (Currently Amended) The method of claim 19, wherein activating said Robo-4 receptor comprises providing a ligand of capable of activating said Robo-4 receptor and ~~allowing the ligand to bind to said Robo-4 receptor~~ exposing the endothelium tissue to the ligand, wherein said exposure of said endothelium tissue to said ligand inhibits migration of endothelial cells.

21. (Currently Amended) The method of claim 20, wherein ~~the ligand comprises~~ providing a ligand capable of activating said Robo-4 receptor comprises providing a Slit ligand.

22. (Currently Amended) The method according to ~~any of claims claim 7, 10, and 8 or claim~~ 20, wherein the ligand comprises providing a ligand capable of activating

U.S. Patent Application Serial No. 10/519,342  
Amendment and Response to Office Action 10/29/2008  
Reply to Office Action of April 29, 2008

said Robo-4 receptor comprises providing a human Slit2 ligand, or a fragment thereof.